Specialties – Page 9

Retifanlimab Plus Chemotherapy Significantly Prolongs Survival in Metastatic NSCLC: Insights from the POD1UM-304 Phase 3 Trial

By MedXY 10/15/2025

The POD1UM-304 study demonstrated that adding the PD-1 inhibitor retifanlimab to platinum-based chemotherapy significantly improves overall survival in patients with first-line metastatic non-small-cell lung cancer, offering a new therapeutic option with manageable safety.

news Oncology Respiratory

Radiotherapy-Free Pembrolizumab Plus Chemotherapy Shows Promise for Locally Advanced NSCLC With High PD-L1 Expression

By MedXY 10/15/2025

The Evolution trial evaluated pembrolizumab combined with chemotherapy without radiotherapy in unresectable, locally advanced NSCLC patients with PD-L1 TPS ≥50%, showing a 2-year progression-free survival rate of 67% and manageable safety profile, suggesting a viable alternative treatment approach.

General Surgery news

Optimizing Mesh Weight to Reduce Recurrence Reoperations in Laparoscopic Inguinal Hernia Repair

By MedXY 10/15/2025

A Danish cohort study identifies that using mesh weighing 45-65 g/m² in laparoscopic inguinal hernia repair results in the lowest reoperation rate for recurrence, guiding surgical mesh selection for better patient outcomes.

Cardiology Hematology-Oncology news

Clonal Hematopoiesis in Older Adults: Implications for Cardiovascular Risk, Bleeding, and Aspirin Use

By MedXY 10/15/2025

This study reveals that clonal hematopoiesis of indeterminate potential (CHIP) in adults aged 70+ does not increase cardiovascular risk but is associated with heightened bleeding risk. Aspirin showed no additional benefits or harms for those with CHIP in primary prevention of cardiovascular events.

Family Medicine & Nutrition news Psychiatry

Comparative Effectiveness of PTSD Treatments in Primary Care: Insights from a Pragmatic Randomized Trial

By MedXY 10/15/2025

A pragmatic trial comparing SSRIs and written exposure therapy in primary care PTSD treatment found similar effectiveness initially; switching to SNRI was superior to WET augmentation for SSRI nonresponders.

news Psychiatry Public Health

Rising Trends in Stimulant Use Disorder Diagnoses Among Adolescent and Young Adult Medicaid Enrollees: Implications for Clinical Practice

By MedXY 10/15/2025

Stimulant use disorder diagnoses in young adult Medicaid enrollees have markedly increased from 2001 to 2020, especially for noncocaine psychostimulants, highlighting an urgent need for targeted interventions and evidence-based treatments amid rising overdose risks.

Dermatology Nephrology news

Enhancing Skin Cancer Surveillance in Solid Organ Transplant Recipients: Impact of the KP-SUNTRAC Risk-Based Program

By MedXY 10/15/2025

A retrospective cohort study demonstrates that implementation of KP-SUNTRAC increases targeted skin cancer screening and detection among high-risk solid organ transplant recipients without increasing health care utilization.

Hematology-Oncology news

Innovative Combination Therapy with Talquetamab and Daratumumab Shows Promise in Heavily Pretreated Multiple Myeloma

By MedXY 10/14/2025

The TRIMM-2 study reveals that talquetamab plus daratumumab yields high response rates and durable disease control in relapsed/refractory multiple myeloma with manageable safety, offering a novel combination strategy for heavily pretreated patients.

Hematology-Oncology news Rheumatology

Azacitidine Shows Promising Efficacy and Safety in Treating VEXAS Syndrome: Insights from a Large-Scale Retrospective FRENVEX Study

By MedXY 10/14/2025

A retrospective study of 88 patients with genetically confirmed VEXAS syndrome reveals that azacitidine improves inflammatory symptoms, cytopenias, and reduces UBA1 mutant clone burden with an acceptable safety profile, supporting its use and need for prospective trials.

Cardiology news

Dual Versus Single Antiplatelet Therapy After Valve-in-Valve TAVI: Balancing Stroke Prevention and Bleeding Risk

By MedXY 10/14/2025

This study compares dual and single antiplatelet therapy after valve-in-valve transcatheter aortic valve implantation, finding dual therapy reduces stroke risk without increasing bleeding or valve deterioration at one year.

Cardiology Specialties

CDKL1 Variants and Their Role in Thoracic Aortic Aneurysm and Dissection: Illuminating Cilia-Linked Pathogenesis

By MedXY 10/14/2025

This study identifies CDKL1 gene variants impairing ciliary function as novel genetic contributors to thoracic aortic aneurysm and dissection, highlighting an emerging pathogenic link between cilia biology and vascular disease.

Hematology-Oncology news Oncology

Defining a Distinct Subtype of TP53-Mutated AML via BAP1 Loss: Implications for Targeted Therapy with BCL-xL Inhibitors

By MedXY 10/14/2025

Loss of the tumor suppressor BAP1 characterizes a unique subtype of TP53-mutated de novo acute myeloid leukemia (AML), correlating with poorer prognosis and erythroid lineage priming, while revealing vulnerability to BCL-xL inhibition as a promising therapeutic strategy.

Hematology-Oncology news Rheumatology

UBA6: A Novel Therapeutic Vulnerability in VEXAS Syndrome Unveiled by E1 Enzyme Dependency Profiling

By MedXY 10/14/2025

This study characterizes UBA1 mutation effects in VEXAS syndrome and identifies UBA6 as a compensatory enzyme and promising therapeutic target, highlighting selective inhibition to combat mutant hematopoietic clones.

Hematology-Oncology Rheumatology Specialties

VEXAS Anemia: Unraveling the Mosaic Erythroblastopenia in a Novel Autoinflammatory Syndrome

By MedXY 10/14/2025

This study reveals that VEXAS syndrome-associated anemia results from a mosaic erythroblastopenia due to selective UBA1 mutations in early erythroid precursors, advancing understanding of its pathophysiology and therapeutic implications.

Hematology-Oncology news Oncology

Enhancing BCMA-CAR T Cell Therapy in Multiple Myeloma Through Glutamine Metabolism Reprogramming

By MedXY 10/14/2025

Reprogramming glutamine metabolism via Asct2 transporter expression improves BCMA-CAR T cell fitness, proliferation, and anti-myeloma efficacy under glutamine-limited conditions, offering a promising strategy to overcome metabolic immune evasion in multiple myeloma.

Hematology-Oncology Specialties

Decoding Response-Adapted Daratumumab Therapy in Elderly Multiple Myeloma: Biomarkers and Mechanisms of Sensitivity and Resistance

By MedXY 10/14/2025

A response-adapted trial of daratumumab monotherapy in elderly newly diagnosed multiple myeloma reveals key biomarkers—CD38 expression, plasma cell phenotype, and immune microenvironment—that predict treatment sensitivity and inform therapeutic escalation strategies.

Hematology-Oncology Infectious Diseases news

Decoding Epstein-Barr Virus Genomic Alterations: Implications for Human Malignancies and Disease Pathogenesis

By MedXY 10/14/2025

A comprehensive genomic analysis of Epstein-Barr virus (EBV) reveals distinct single nucleotide and structural variations linked to various human diseases, especially hematological malignancies, highlighting viral mechanisms underlying pathogenesis and potential therapeutic targets.

Hematology-Oncology news

Enhancing Patient Experience in DLBCL: Insights from PROs and Clinician-Reported AEs in the Phase 3 POLARIX Trial

By MedXY 10/14/2025

The POLARIX trial demonstrates superior progression-free survival with Pola-R-CHP in untreated DLBCL, highlighting the utility of patient-reported outcomes alongside clinician-reported adverse events to capture symptom burden and quality of life comprehensively.

Hematology-Oncology news

Decoding Progression Risk in IgM-MGUS and Asymptomatic Waldenström Macroglobulinemia Through Genomic Profiling

By MedXY 10/14/2025

This article explores how genomic features differentiate stable from progressive asymptomatic Waldenström macroglobulinemia and IgM-MGUS, highlighting mutation burdens, specific gene alterations, and aneuploidy as prognostic markers for disease progression.

Hematology-Oncology news

Genetic Architecture of Myeloproliferative Neoplasm Subtypes: Uncovering a Novel Sex-Specific Association at CDH22/CD40

By MedXY 10/14/2025

A large genome-wide analysis identifies multiple genetic loci influencing MPN subtypes and reveals a female-specific variant at CDH22/CD40, enhancing understanding of disease heterogeneity and potential for personalized risk stratification.